NCT00580073 - Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Rectal Cancer

Interventions

DRUG

FOLFOX4

oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)

DRUG

Cetuximab

Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.

Trial Locations (1)

53792

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison